BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11733623)

  • 1. Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease.
    Schiavello T; Burke V; Bogdanova N; Jasik P; Melsom S; Boudville N; Robertson K; Angelicheva D; Dworniczak B; Lemmens M; Horst J; Todorov V; Dimitrakov D; Sulowicz W; Krasniak A; Stompor T; Beilin L; Hallmayer J; Kalaydjieva L; Thomas M
    Nephrol Dial Transplant; 2001 Dec; 16(12):2323-7. PubMed ID: 11733623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACE insertion/deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease.
    van Dijk MA; Breuning MH; Peters DJ; Chang PC
    Nephrol Dial Transplant; 2000 Jun; 15(6):836-9. PubMed ID: 10831637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the alpha-adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic kidney disease.
    Merta M; Reiterová J; Stekrová J; Rysava R; Rihová Z; Tesar V; Viklický O; Kmentova D
    Kidney Blood Press Res; 2003; 26(1):42-9. PubMed ID: 12697976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis.
    Pereira TV; Nunes AC; Rudnicki M; Magistroni R; Albertazzi A; Pereira AC; Krieger JE
    Nephrol Dial Transplant; 2006 Nov; 21(11):3155-63. PubMed ID: 16935894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the ACE gene polymorphism with the progression of autosomal dominant polycystic kidney disease.
    Lee KB; Kim UK; Lee CC
    J Korean Med Sci; 2000 Aug; 15(4):431-5. PubMed ID: 10983692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease.
    Baboolal K; Ravine D; Daniels J; Williams N; Holmans P; Coles GA; Williams JD
    Kidney Int; 1997 Sep; 52(3):607-13. PubMed ID: 9291178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease.
    Pérez-Oller L; Torra R; Badenas C; Milà M; Darnell A
    Am J Kidney Dis; 1999 Aug; 34(2):273-8. PubMed ID: 10430974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of angiotensin converting enzyme (
    Ramanathan G; Ghosh S; Elumalai R; Periyasamy S; Lakkakula BV
    Indian J Med Res; 2016 Jun; 143(6):748-755. PubMed ID: 27748299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of ACE (I/D) and G460W polymorphism of alpha-adducin in autosomal dominant polycystic kidney disease.
    Persu A; El-Khattabi O; Messiaen T; Pirson Y; Chauveau D; Devuyst O
    Nephrol Dial Transplant; 2003 Oct; 18(10):2032-8. PubMed ID: 13679477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between angiotensin converting enzyme gene polymorphism and clinical features in autosomal dominant polycystic kidney disease.
    Uemasu J; Nakaoka A; Kawasaki H; Ishikawa I; Yoshino Y; Shio H; Nemoto R; Nakamura I; Morio S
    Life Sci; 1997; 60(23):2139-44. PubMed ID: 9180368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
    Ecder T; McFann KK; Raynolds MV; Schrier RW
    Am J Nephrol; 2003; 23(6):466-70. PubMed ID: 14600431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy.
    Merta M; Reiterová J; Tesar V; Stekrová J; Viklický O
    Ren Fail; 2002 Sep; 24(5):585-93. PubMed ID: 12380903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE gene I/D polymorphism and the presence of renal failure or hypertension in autosomal dominant polycystic kidney disease (ADPKD).
    Gumprecht J; Zychma MJ; Karasek D; Grzeszczak W
    Nephrol Dial Transplant; 2007 May; 22(5):1483. PubMed ID: 17205958
    [No Abstract]   [Full Text] [Related]  

  • 14. The angiotensin-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease.
    van Dijk MA; Peters DJ; Breuning MH; Chang PC
    J Am Soc Nephrol; 1999 Sep; 10(9):1916-20. PubMed ID: 10477143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ACE I/D gene polymorphism on congenital renal malformations.
    Hohenfellner K; Wingen AM; Nauroth O; Wühl E; Mehls O; Schaefer F
    Pediatr Nephrol; 2001 Apr; 16(4):356-61. PubMed ID: 11354781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of G-protein beta3-subunit gene and endothelial nitric oxide synthase gene in exon 7 polymorphisms on progression of autosomal dominant polycystic kidney disease.
    Reiterová J; Miroslav M; Stekrová J; Kohoutová M; Tesar V; Kmentová D; Hubácek JA; Viklický O
    Ren Fail; 2004 Mar; 26(2):119-25. PubMed ID: 15287194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin I-converting enzyme gene polymorphism in non-diabetic renal disease.
    Samuelsson O; Attman PO; Larsson R; Mulec H; Rymo L; Weiss L; Ricksten A
    Nephrol Dial Transplant; 2000 Apr; 15(4):481-6. PubMed ID: 10727542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population.
    Jalil JE; Piddo AM; Cordova S; Chamorro G; Braun S; Jalil R; Vega J; Jadue'P L; Lavandero S; Lastra P
    Am J Hypertens; 1999 Jul; 12(7):697-704. PubMed ID: 10411367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy.
    Merta M; Reiterová J; Tesar V; Stekrová J; Viklický O
    Ren Fail; 2002 Jul; 24(4):467-75. PubMed ID: 12212826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.